Clinical Trials · NCT05313529
LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Enrollment
- 396
- Start date
- Oct 2022
- Locations
- 5 sites, China
- Primary endpoint
- Mild cognitive impairment (MCI) remission rate